New results on Proclarix® resolving indeterminate Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis will be presented at the 37th Annual EAU Congress in Amsterdam, NL.

Zurich-Schlieren, Switzerland, June 29, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that new data will be presented showing that Proclarix^® can be used with high confidence by reliably identifying clinically significant prostate cancer and safely ruling out negative cases.

Study results will be presented during the 37^th Annual European Association of Urology (EAU) Congress in Amsterdam, NL in the following session:

Abstract Session 26: PCa localised imaging grade prediction, reporting and markers – Sunday, July 03 2022, 10:30 – 12:00, Yellow Area, Room Forum.

Abstract A0481 – A0481: Proclarix aids in resolving indeterminate multi-parametric magnetic resonance imaging for the improved diagnosis of prostate cancer.

Presenter: M. Campistol Torres, Universitat Autònoma de Barcelona, Vall d’Hebron University Hospital, Barcelona, Spain.

Authors: Campistol Torres M.¹, Morote J.¹, Pye H.², Athanasiou A.³, Celma A.¹, Regis L.¹, Planas J.¹, Santamaria A.¹, Trilla E.¹, Schiess R.³, Punwani S.⁴, Whitaker H.², Ahmed H.U.⁵, Emberton M.⁶Institutions: ¹Hospital Vall d’Hebron, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ²University College London, Molecular Diagnostics and Therapeutics Group, London, United Kingdom, ³Proteomedix AG, Dept. of Research & Development, Zurich-Schlieren, Switzerland, ⁴University College London, Centre for Medical Imaging, London, United Kingdom, ⁵Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, ⁶University College London, Division of Surgery and Interventional Science, London, United Kingdom